Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13041957 | 0.76 | DYRK1A (0.36) | DYRK1ANFATC1GSK3BMEN1KMT2A | |
| SCHEMBL19759421 | 0.73 | KDM4E (0.33) | — | |
| SCHEMBL10212549 | 0.72 | MAPKAPK2 (0.44) | — | |
| SCHEMBL21375598 | 0.71 | TDP1 (0.46) | GSK3BMEN1LMNAMAPTHTT | |
| SCHEMBL29638555 | 0.69 | RPS6KB1 (0.40) | TDP1 | |
| SCHEMBL23103354 | 0.68 | MEN1 (0.33) | DYRK1ANFATC1GSK3BMEN1LMNA | |
| SCHEMBL16019431 | 0.68 | DYRK1A (0.56) | DYRK1ANFATC1GSK3BMEN1LMNA | |
| SCHEMBL2628318 | 0.68 | RPS6KA5 (0.32) | MAPT | |
| SCHEMBL19759425 | 0.66 | EGFR (0.33) | — | |
| SCHEMBL23809363 | 0.65 | NR4A2 (0.41) | DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210015915-A1 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015915-A1 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | STING1, CGAS, TBK1 | DYRK1A 3348/4885NFATC1 68/4885GSK3B 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.